This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JOSEPH H. ROHR, M.D.; ARTHUR R. COLWELL, M.D.

Arch Intern Med. 1948;82(1):54-62.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THERE has been constant and increasing interest in the time action of modified insulins in the search for an ideal preparation capable of providing good control for the greatest number of diabetic patients by a single daily injection. The introduction of protamine insulin by Hagedorn¹ in 1936 was a major contribution, and in a large number of cases the diabetes is satisfactorily controlled with single daily injections of protamine zinc insulin. However, it is evident that its time action is too prolonged for ideal purposes. Postprandial glycosuria and nocturnal reactions occur in many patients, particularly those with severe grades of diabetes. The need for an insulin with activity intermediate between that of regular insulin and that of protamine zinc insulin led to the development of globin insulin with zinc in 1939 by Reiner, Searle and Lang.² This product has also been referred to as globin zinc insulin and . . . [Full Text PDF of this Article]

Author Affiliations
CHICAGO

From the Diabetic Service of Wesley Memorial Hospital and the Northwestern University Medical School, Department of Medicine.

Footnotes
Aided by a grant from Burroughs-Wellcome & Co. (U. S. A.), Inc.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?